Deepcell

Deepcell

Biotechnology for cell analysis and sorting

About Deepcell

Simplify's Rating
Why Deepcell is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

Data & Analytics

AI & Machine Learning

Biotechnology

Company Size

11-50

Company Stage

Late Stage VC

Total Funding

$173.1M

Headquarters

Sunnyvale, California

Founded

2015

Overview

Deepcell specializes in biotechnology focused on cell analysis and sorting. The main product, the REM-I platform, utilizes label-free imaging and deep learning to analyze and categorize cells based on their shape and structure. This technology provides detailed data about individual cells through advanced microfluidics and artificial intelligence, allowing for comprehensive cell characterization. Clients include pharmaceutical companies and academic researchers who require precise cell analysis for drug development and disease studies. Deepcell differentiates itself by combining microfluidics with AI to offer in-depth insights, and it aims to support scientific and medical research through its innovative cell analysis solutions.

Simplify Jobs

Simplify's Take

What believers are saying

  • Deepcell is raising $80M to expand and accelerate product development.
  • Demand for label-free imaging technologies is increasing, aligning with Deepcell's offerings.
  • AI in translational research is expanding, enhancing Deepcell's value proposition.

What critics are saying

  • Emerging competition from companies like Berkeley Lights could impact Deepcell's market share.
  • Rapid technological advancements may require costly updates to Deepcell's REM-I platform.
  • Potential ethical concerns and regulatory scrutiny could slow product adoption.

What makes Deepcell unique

  • Deepcell's REM-I platform combines label-free imaging with deep learning for cell analysis.
  • The company uses advanced microfluidics for precise cell sorting and analysis.
  • Deepcell's AI-driven technology provides high-dimensional quantitative readouts of individual cells.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$173.1M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:
Late VC funding comparison data is currently unavailable. We're working to provide this information soon!
Late VC Funding Comparison
Coming Soon

Growth & Insights and Company News

Headcount

6 month growth

-7%

1 year growth

-7%

2 year growth

26%
Intelligence360
Oct 26th, 2022
Menlo Park California Based Deepcell Is Raising $80,000,095.00 In New Equity Investment.

Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Deepcell is raising $80,000,095.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mahdokht Masaeli played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development. About Deepcell

Clinical Omics
Dec 9th, 2020
Deepcell receives financing of $20M in Series A financing

Deepcell, a developer of artificial intelligence-based cell classification and isolation technologies spun out of Stanford University in 2017, said this week it has completed a $20 million Series A financing.

Finsmes
Dec 7th, 2020
Deepcell Closes $20M Series A Funding Round

Deepcell, a Mountain View, Calif.-based life science company pioneering AI-powered cell classification and isolation for cell biology and translational research, closed its Series A round of financing with $20m. The round was led by Bow Capital and joined by Andreessen Horowitz, which led its $5m seed round. Other investors include 50Y, DCVC, Stanford University, and […]

Recently Posted Jobs

Sign up to get curated job recommendations

There are no jobs for Deepcell right now.

Find jobs on Simplify and start your career today

💡
Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →